December 3, 2020 -- The U.S. government has purchased an additional 650,000 doses of Eli Lilly's neutralizing antibody, bamlanivimab, for $812.5 million.
The doses will be delivered through the end of January 2021 with at least 350,000 doses being delivered in December 2020. Bamlanivimab received for emergency use authorization for the treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.
The purchase brings the total doses purchased by the U.S. government to 950,000. According to the government, Americans will have no out-of-pocket costs for the medicine. The federal government is responsible for allocation of the drug, with weekly allocation decisions made based on confirmed COVID-19 cases in each state and territory over the previous seven days.